mRNA Vaccines Beyond COVID-19: What’s Next for Infectious Diseases?

mRNA Vaccines Beyond COVID-19 What’s Next for Infectious Diseases

---

---

 

---

---

Introduction

The COVID-19 pandemic transformed messenger RNA vaccine technology from a largely experimental platform into a widely deployed public health intervention. Although foundational research on mRNA therapeutics began several decades ago, early efforts were limited by challenges related to molecular instability, inefficient cellular delivery, and excessive innate immune activation. Prior to 2020, mRNA vaccines had not achieved regulatory approval for human use despite promising preclinical and early phase clinical data. The urgency of the pandemic created unprecedented scientific collaboration, substantial public and private investment, streamlined regulatory pathways, and large scale clinical trial enrollment. These factors collectively enabled the rapid development, testing, and emergency authorization of the first mRNA vaccines in late 2020, establishing proof of concept for the platform in real world settings.

mRNA vaccines operate through a fundamentally different mechanism compared with traditional vaccine approaches. Instead of introducing attenuated or inactivated pathogens, or recombinant protein antigens, mRNA vaccines deliver synthetic messenger RNA encoding a specific antigen into host cells. Once inside the cytoplasm, the mRNA is translated by cellular machinery into the encoded protein antigen, which is subsequently processed and presented to the immune system. This process stimulates both humoral and cellular immune responses, including neutralizing antibodies and antigen specific T cell activation. The use of lipid nanoparticle delivery systems enhances cellular uptake and protects the mRNA from rapid degradation. Importantly, the mRNA does not integrate into the host genome and is transiently expressed before being naturally degraded.

The platform offers several theoretical and practical advantages. First, mRNA vaccine design can be rapidly adapted once the genetic sequence of a pathogen is known, significantly shortening development timelines compared with conventional vaccine production methods. Second, manufacturing relies on cell free, synthetic processes that can be scaled efficiently and modified to address emerging variants. Third, the ability to encode multiple antigens within a single construct provides flexibility for multivalent or combination vaccines. These features position mRNA technology as a potentially transformative tool in infectious disease prevention.

Following the demonstrated efficacy of mRNA vaccines against SARS CoV 2, there has been substantial interest in extending this platform to other infectious diseases. Active research programs are targeting seasonal influenza, respiratory syncytial virus, cytomegalovirus, human immunodeficiency virus, Zika virus, and several neglected tropical diseases. Influenza represents a particularly promising application, as the rapid adaptability of mRNA constructs could improve strain matching and vaccine effectiveness in comparison to egg based production systems. Similarly, pathogens that have historically eluded effective vaccine development due to antigenic variability or complex immune evasion strategies may benefit from iterative mRNA design and optimization.

In addition to infectious diseases, exploratory investigations are assessing mRNA technology for therapeutic vaccines in oncology and for personalized immunization strategies. While these applications extend beyond the scope of this review, they underscore the broader potential of mRNA platforms in precision medicine.

Despite the enthusiasm surrounding mRNA vaccines, important considerations remain. Long term durability of immune responses, optimal dosing strategies, cold chain logistics, cost effectiveness, and equitable global distribution require continued evaluation. Safety monitoring remains essential, particularly in relation to rare adverse events identified during post authorization surveillance. Furthermore, public trust and vaccine acceptance are critical determinants of real world impact.

This paper examines the evolving landscape of mRNA vaccine development beyond COVID 19, focusing on the scientific rationale for platform expansion, current progress across key disease targets, and anticipated clinical implications. By synthesizing emerging evidence, the analysis aims to provide a balanced and evidence based assessment of how mRNA technology may shape the future of infectious disease prevention. As research advances and manufacturing capabilities mature, mRNA vaccines are poised to play an increasingly central role in global immunization strategies, provided that scientific, logistical, and ethical challenges are addressed in parallel.

---

Current State of mRNA Vaccine Technology

Mechanism of Action

mRNA vaccines deliver synthetic messenger RNA encoding specific antigens into host cells. Following cellular uptake, ribosomes translate the mRNA into proteins that serve as antigens. These antigens are processed and presented to immune cells, triggering both cellular and humoral immune responses.

The mRNA sequence is modified to enhance stability and translation efficiency. Pseudouridine modifications replace natural uridine residues, reducing innate immune activation and increasing protein production. The mRNA is encapsulated in lipid nanoparticles that facilitate cellular uptake and protect against degradation.

Several factors influence mRNA vaccine effectiveness. Antigen selection determines the specificity of immune responses. Delivery systems affect cellular uptake and distribution. Formulation components influence stability and immunogenicity. These variables can be modified to optimize vaccines for specific pathogens and patient populations.

Advantages of mRNA Platforms

mRNA vaccines offer several potential advantages over conventional vaccine approaches. Development timelines are typically shorter because the platform does not require pathogen cultivation or inactivation processes. Once target antigens are identified, mRNA sequences can be designed and synthesized rapidly.

Manufacturing processes are standardized across different vaccines using the same platform. This approach allows for rapid scaling when addressing emerging infectious diseases. The platform also enables quick adaptation to variant strains by modifying mRNA sequences encoding updated antigens.

Safety profiles may be favorable because mRNA vaccines do not contain live pathogens. The mRNA is temporary and does not integrate into host genomes. Adverse reactions are typically limited to injection site reactions and systemic inflammatory responses similar to other vaccines.

Immune responses generated by mRNA vaccines can include both antibody production and T-cell activation. This dual response may provide broader protection compared to vaccines that primarily stimulate antibody responses. The flexibility of mRNA platforms also allows for multivalent formulations targeting multiple pathogens simultaneously.

Current Limitations

Despite advantages, mRNA vaccine technology faces several limitations. Storage and distribution require ultra-low temperatures for some formulations, creating logistical challenges. Recent formulations have improved temperature stability, but cold chain requirements remain more demanding than traditional vaccines.

Manufacturing costs are currently higher than conventional vaccine production. Lipid nanoparticle components are expensive, and specialized equipment is required. Scale-up challenges may limit global accessibility, particularly in resource-limited settings.

Duration of protection from mRNA vaccines requires further study. COVID-19 vaccine experience suggests that booster doses may be necessary to maintain immunity. The optimal timing and frequency of boosters for different diseases remain under investigation.

Reactogenicity profiles show higher rates of fever and systemic reactions compared to some traditional vaccines. While generally mild and temporary, these reactions may affect acceptance and compliance with vaccination schedules.

---

Applications in Viral Diseases

Influenza Vaccines

Seasonal influenza vaccination represents a major target for mRNA vaccine development. Current influenza vaccines require annual updates to match circulating strains and show variable effectiveness. mRNA platforms could improve upon these limitations through faster strain matching and enhanced immune responses.

Multiple companies are developing mRNA influenza vaccines. Early clinical trials have demonstrated safety and immunogenicity comparable to or exceeding traditional influenza vaccines. Phase 1 and 2 trials show promising antibody responses against vaccine strains.

One advantage of mRNA influenza vaccines is the potential for rapid strain updates. Traditional vaccine production requires months to adapt to new strains, but mRNA vaccines could be updated within weeks. This capability may improve vaccine effectiveness during seasons when circulating strains differ from predicted strains.

Multivalent mRNA influenza vaccines are under development. These formulations could protect against more influenza strains than current quadrivalent vaccines. Some experimental vaccines target conserved influenza proteins to provide broader, longer-lasting protection across multiple strains and subtypes.

Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) causes serious illness in infants, young children, and older adults. No vaccines were available until recently, when protein-based vaccines received approval for specific populations. mRNA vaccines represent an alternative approach for RSV prevention.

Several mRNA RSV vaccines are in clinical development. These vaccines target the RSV fusion protein, which is essential for viral entry into cells. Early trial results show strong antibody responses and favorable safety profiles.

RSV vaccines face unique challenges due to previous vaccine failures that resulted in enhanced disease severity. mRNA RSV vaccines use stabilized versions of the fusion protein to avoid these problems. Preclinical studies suggest that properly designed mRNA vaccines do not cause enhanced disease.

Maternal immunization strategies are being investigated for RSV prevention in newborns. Pregnant women would receive mRNA RSV vaccines to generate antibodies that transfer to infants through placental circulation. This approach could protect infants during their most vulnerable period.

Cytomegalovirus

Cytomegalovirus (CMV) infection causes serious complications in immunocompromised patients and congenital infections in newborns. Current prevention strategies are limited, making CMV vaccine development a priority.

mRNA CMV vaccines are being tested in clinical trials. These vaccines target multiple CMV antigens to generate broad immune responses. Early results show antibody production and T-cell responses against CMV-infected cells.

CMV vaccine development is challenging because the virus has multiple mechanisms for immune evasion. mRNA vaccines may overcome some of these challenges by generating strong T-cell responses that can recognize CMV-infected cells despite viral immune evasion strategies.

Target populations for CMV vaccines include transplant recipients, pregnant women, and healthcare workers. Each population has specific requirements for vaccine safety and efficacy. Clinical trials are evaluating different formulations and dosing schedules for these groups.

Zika Virus

Zika virus emerged as a global health threat due to its association with birth defects and neurological complications. The epidemic highlighted the need for rapid vaccine development against emerging infectious diseases.

mRNA Zika vaccines demonstrated rapid development capabilities during the outbreak. Vaccines were designed and entered clinical trials within months of the epidemic declaration. This timeline was much faster than traditional vaccine development approaches.

Clinical trials of mRNA Zika vaccines show good safety profiles and antibody responses. The vaccines generate neutralizing antibodies that protect against Zika virus infection in animal models. Human efficacy trials have been limited by the decline in Zika transmission.

Zika vaccine development illustrates both the potential and challenges of mRNA platforms for emerging diseases. While vaccines can be developed quickly, conducting efficacy trials during declining epidemics is difficult. This pattern may repeat with other emerging infectious diseases.

 

---

Applications in Bacterial and Parasitic Diseases

Tuberculosis

Tuberculosis remains a leading cause of infectious disease mortality worldwide. Current vaccination relies on the Bacille Calmette-Guérin (BCG) vaccine, which provides limited protection against pulmonary tuberculosis in adults. New approaches are needed to control this global health problem.

mRNA vaccines for tuberculosis are in early development stages. These vaccines target multiple Mycobacterium tuberculosis antigens that are expressed during different phases of infection. The goal is to generate immune responses that prevent infection or progression to active disease.

Challenges in tuberculosis vaccine development include the complex pathogenesis of infection and the need for long-term protection. mRNA vaccines may address some of these challenges through their ability to generate both antibody and T-cell responses, which are both important for tuberculosis control.

Target populations for tuberculosis vaccines include healthcare workers, household contacts of patients, and individuals in high-transmission settings. Clinical trials will need to demonstrate both safety and efficacy in these populations over extended follow-up periods.

Malaria

Malaria prevention has relied primarily on vector control and chemoprevention strategies. Vaccine development has been challenging due to the complex life cycle of malaria parasites and their immune evasion mechanisms.

mRNA malaria vaccines represent a new approach to this persistent global health challenge. These vaccines can target multiple stages of the parasite life cycle, potentially providing broader protection than single-antigen vaccines.

Research is focusing on targeting sporozoite, liver stage, and blood stage antigens of Plasmodium falciparum. Multivalent mRNA vaccines could generate immune responses against multiple parasite stages simultaneously, improving overall vaccine effectiveness.

The flexibility of mRNA platforms may be particularly valuable for malaria vaccines because it allows rapid adaptation to different parasite strains and species. This capability could address the genetic diversity that has complicated traditional malaria vaccine development.

 

---

Clinical Development Pipeline

Current Clinical Trials

Table 1 summarizes selected mRNA vaccine clinical trials for diseases other than COVID-19 as of 2024.

Disease	Sponsor	Phase	Target Antigen	Study Population
Influenza	Moderna	Phase 3	Hemagglutinin	Adults 18+
RSV	Pfizer	Phase 2	Fusion protein	Adults 60+
CMV	Moderna	Phase 2	Multiple antigens	Transplant candidates
Zika	NIH/Moderna	Phase 2	Envelope protein	Adults in endemic areas
RSV maternal	Pfizer	Phase 2	Fusion protein	Pregnant women

The clinical development pipeline includes vaccines in various stages of testing. Phase 1 trials focus on safety and immune responses in small groups. Phase 2 trials expand to larger populations and may include efficacy endpoints. Phase 3 trials provide definitive evidence of efficacy and safety for regulatory approval.

Several factors influence the progression of these trials. Disease epidemiology affects the ability to measure vaccine efficacy. Regulatory requirements vary by disease and target population. Manufacturing capacity limits the number of vaccines that can advance simultaneously.

Regulatory Considerations

Regulatory approval of mRNA vaccines for new diseases will build upon experience gained during COVID-19 vaccine development. However, each disease presents unique regulatory challenges and requirements.

Safety evaluation must demonstrate acceptable risk-benefit profiles for each indication. This evaluation is particularly important for vaccines targeting diseases with low mortality rates or vaccines intended for healthy populations such as children.

Efficacy standards vary by disease and available alternatives. Vaccines for diseases without existing prevention methods may have different approval thresholds than vaccines competing with established interventions.

International harmonization of regulatory standards could accelerate global access to new mRNA vaccines. However, different regulatory agencies may have varying requirements based on local epidemiology and healthcare priorities.

---

Challenges and Limitations

Technical Challenges

Several technical challenges must be addressed for successful mRNA vaccine development beyond COVID-19. Antigen selection requires understanding of protective immune responses for each disease. This knowledge is well-established for some diseases but limited for others.

Delivery system optimization may need disease-specific modifications. Different target cell types and tissue distribution requirements could necessitate specialized lipid nanoparticle formulations or alternative delivery approaches.

Stability improvements remain important for global deployment. While temperature stability has improved, many settings still lack adequate cold storage infrastructure. Further formulation advances could expand access in resource-limited environments.

Manufacturing scalability presents ongoing challenges. Current production capacity is focused on COVID-19 vaccines, limiting resources for other diseases. Expanding manufacturing requires substantial investments and technical expertise.

Economic and Access Issues

Cost considerations affect the development and deployment of new mRNA vaccines. Development costs are high, particularly for diseases affecting primarily low-income populations. Market incentives may not support development of vaccines for neglected tropical diseases.

Pricing strategies must balance development costs with global accessibility needs. Tiered pricing approaches could improve access while maintaining development incentives. Public-private partnerships may be necessary for diseases with limited commercial markets.

Intellectual property issues could limit global access to mRNA vaccine technology. Patent protections may restrict manufacturing to licensed facilities, potentially limiting supply and increasing costs. Licensing agreements and technology transfer could address these limitations.

Infrastructure requirements for mRNA vaccine deployment may exceed capacity in some settings. Cold chain requirements, trained personnel, and healthcare delivery systems all influence successful vaccine implementation.

Safety and Acceptance Considerations

Long-term safety data for mRNA vaccines remain limited to COVID-19 experience. While no long-term safety signals have emerged, continued monitoring is essential as the technology is applied to new diseases and populations.

Reactogenicity profiles may affect vaccine acceptance, particularly for diseases perceived as lower risk. Higher rates of fever and systemic reactions compared to some traditional vaccines could influence patient and provider decisions.

Public acceptance of mRNA vaccine technology may vary by population and disease. Experience with COVID-19 vaccines, both positive and negative, will influence attitudes toward future mRNA vaccines.

Healthcare provider education will be important for successful implementation. Providers need accurate information about mRNA vaccine technology, benefits, and risks to make appropriate recommendations to patients.

---

Comparative Analysis with Traditional Vaccines

Development Timelines

mRNA vaccines offer faster development timelines compared to traditional vaccine approaches. Traditional vaccines may require years to develop, test, and manufacture. mRNA vaccines can potentially be developed and tested within months.

This speed advantage is most apparent during health emergencies when rapid response is critical. For routine vaccine development, the time savings may be less dramatic due to similar clinical trial requirements and regulatory processes.

However, the ability to rapidly modify mRNA vaccines for variant strains or updated formulations provides ongoing advantages. Traditional vaccines require more extensive reformulation processes that can delay availability of updated vaccines.

Efficacy Comparisons

Direct efficacy comparisons between mRNA and traditional vaccines are limited because few head-to-head trials have been conducted. Available data suggest that mRNA vaccines can achieve efficacy levels comparable to or exceeding traditional vaccines for some diseases.

Immune response patterns may differ between mRNA and traditional vaccines. mRNA vaccines typically generate strong T-cell responses in addition to antibody responses. This difference could translate to superior protection for some diseases, particularly those requiring cellular immunity.

Duration of protection comparisons are limited by the recent introduction of mRNA vaccines. Long-term studies will be necessary to determine whether mRNA vaccines provide longer-lasting immunity than traditional vaccines.

Manufacturing and Distribution

Manufacturing processes for mRNA vaccines are standardized across different vaccines using the same platform. This standardization can reduce production costs and time compared to developing unique manufacturing processes for each traditional vaccine.

However, current mRNA vaccine manufacturing costs remain higher than many traditional vaccines. Lipid nanoparticle components are expensive, and specialized equipment requirements increase capital costs.

Distribution requirements for mRNA vaccines typically involve more demanding cold chain needs than traditional vaccines. Recent formulations have improved temperature stability, but requirements generally exceed those for most traditional vaccines.

---

Future Directions and Innovations

Next-Generation Platforms

Research continues on improving mRNA vaccine platforms through various approaches. Self-amplifying RNA vaccines contain additional genetic elements that increase protein production and may enhance immune responses while using lower doses.

Circular RNA platforms offer improved stability compared to linear mRNA. These formulations may reduce degradation and extend protein expression, potentially improving vaccine effectiveness and duration of protection.

Targeted delivery systems are being developed to direct mRNA vaccines to specific cell types or tissues. These approaches could improve vaccine effectiveness while reducing systemic exposure and potential adverse reactions.

Multivalent and Universal Vaccines

Multivalent mRNA vaccines targeting multiple diseases simultaneously are under development. These combination vaccines could reduce the number of vaccinations required and improve compliance with vaccination schedules.

Universal vaccine approaches aim to provide broad protection against multiple strains or species of pathogens. For example, universal influenza vaccines could protect against seasonal and pandemic strains without annual updates.

The flexibility of mRNA platforms makes them well-suited for these approaches. Multiple antigens can be encoded on the same or different mRNA molecules and included in single vaccine formulations.

Personalized Medicine Applications

mRNA vaccine technology may enable personalized approaches to infectious disease prevention. Vaccines could be tailored to individual genetic factors that influence immune responses or disease susceptibility.

Population-specific vaccines might address genetic variations that affect vaccine effectiveness in different ethnic groups. This approach could improve vaccine performance in populations that have shown suboptimal responses to traditional vaccines.

Real-time adaptation to circulating pathogens could become possible with advanced mRNA platforms. Surveillance data could inform rapid updates to vaccine formulations to match currently circulating strains.

---

Global Health Implications

Impact on Disease Control

Successful development of mRNA vaccines for additional diseases could transform global infectious disease control efforts. Diseases that currently lack effective vaccines could become preventable with new mRNA approaches.

The speed of mRNA vaccine development makes this technology particularly valuable for responding to emerging infectious diseases. Future pandemics or epidemic outbreaks could be addressed more rapidly than with traditional vaccine development approaches.

Disease elimination efforts could benefit from improved vaccines with higher efficacy or broader coverage. mRNA vaccines might provide the tools necessary to eliminate diseases that have persisted despite current prevention strategies.

Equity and Access Considerations

Global access to mRNA vaccines requires addressing manufacturing capacity, cost, and infrastructure limitations. Technology transfer to developing countries could improve local production capacity and reduce dependence on imports.

Funding mechanisms for vaccines targeting diseases primarily affecting low-income populations need development. Traditional market-based approaches may not provide adequate incentives for these vaccines.

Capacity building for vaccine deployment includes training healthcare workers, developing cold chain infrastructure, and establishing monitoring systems. These investments are necessary to realize the potential benefits of new mRNA vaccines.

Public Health Policy Implications

Health policy decisions regarding mRNA vaccine adoption will require careful consideration of costs, benefits, and opportunity costs. Policies must address vaccine prioritization, funding, and implementation strategies.

Integration of new mRNA vaccines into existing immunization programs requires coordination and planning. Vaccine schedules may need modification to accommodate new vaccines while maintaining coverage of existing vaccines.

International coordination could improve the effectiveness of mRNA vaccine deployment. Harmonized approaches to vaccine approval, procurement, and distribution could reduce costs and improve global coverage.

---

---

Conclusion   

Key Takeaways

mRNA vaccine technology has demonstrated its potential through successful COVID-19 vaccine development and deployment. The platform offers advantages in development speed, manufacturing flexibility, and immune response generation that make it attractive for addressing other infectious diseases.

Current research pipeline includes vaccines for major diseases such as influenza, RSV, CMV, and Zika virus. Early clinical trial results are encouraging, showing safety profiles and immune responses that support continued development.

Challenges remain in areas including manufacturing costs, temperature stability, and global access. Addressing these challenges will determine the ultimate impact of mRNA vaccines on global infectious disease control.

The technology’s flexibility makes it particularly valuable for emerging infectious diseases and diseases requiring frequent vaccine updates. This capability could improve pandemic preparedness and response to future health threats.

Success of mRNA vaccines beyond COVID-19 will depend on continued research, regulatory approval, and implementation of strategies to ensure global access. The potential benefits justify continued investment in this technology platform.

Frequently Asked Questions:   

What diseases are most likely to have mRNA vaccines available first?

Influenza and RSV vaccines are in advanced clinical trials and may receive approval within the next few years. These diseases have clear market demand and well-understood regulatory pathways.

How do mRNA vaccines compare to traditional vaccines in terms of side effects?

mRNA vaccines typically cause more fever and systemic reactions than some traditional vaccines, but these reactions are generally mild and temporary. Long-term safety profiles appear favorable based on COVID-19 vaccine experience.

Will mRNA vaccines be more expensive than current vaccines?

Current manufacturing costs are higher than traditional vaccines, but costs may decrease with scale and technological improvements. Pricing will likely vary by disease and market factors.

Can mRNA vaccines be combined with traditional vaccines?

Yes, mRNA vaccines can be administered with traditional vaccines. Studies have shown that immune responses and safety profiles remain acceptable when vaccines are given together.

How quickly can mRNA vaccines be updated for new strains?

mRNA vaccines can potentially be updated within weeks once new strain sequences are identified. This speed advantage could improve vaccine effectiveness against rapidly evolving pathogens.

What storage requirements do new mRNA vaccines have?

Storage requirements vary by formulation, but most current mRNA vaccines require refrigeration or freezing. Newer formulations are being developed with improved temperature stability.

Are mRNA vaccines safe for children and pregnant women?

Safety in these populations depends on specific vaccines and clinical trial data. Each vaccine requires separate evaluation in pediatric and pregnant populations before approval for these groups.

Could mRNA vaccines help eliminate certain diseases?

mRNA vaccines could contribute to disease elimination efforts if they provide high efficacy and broad population coverage. Success would depend on factors including vaccine effectiveness, coverage rates, and disease transmission patterns.

 

---

References:  

Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., … & Rajeev, K. G. (2019). The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology, 14(12), 1084-1087.

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., … & Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine, 384(5), 403-416.

Bergmann, C. C., & Silverman, R. H. (2020). COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. Cleveland Clinic Journal of Medicine, 87(6), 321-327.

Carboni, E., Oglesby, I. K., Trudeau, K. M., Nickerson, K. P., Resteau, D., Fasciano, A. C., … & McDonald, C. (2022). Histopathological and transcriptional hallmarks of innate and adaptive immune responses in COVID-19 lungs. Nature Communications, 13(1), 1-15.

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 20(11), 817-838.

Dolgin, E. (2021). The tangled history of mRNA vaccines. Nature, 597(7876), 318-324.

Fiedler, K., Lazzaro, S., Lutz, J., Rauch, S., & Heidenreich, R. (2022). mRNA cancer vaccines. Recent Results in Cancer Research, 214, 61-84.

Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., … & Lebwohl, D. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493-502.

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6(12), 1078-1094.

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., … & Beigel, J. H. (2020). An mRNA vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine, 383(20), 1920-1931.

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165-175.

Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., … & Crowe Jr, J. E. (2016). A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Science Immunology, 1(2), eaah5507.

Lamb, Y. N. (2021). BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs, 81(4), 495-501.

Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., … & Lore, K. (2017). Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Molecular Therapy, 25(12), 2635-2647.

Moderna, Inc. (2023). Pipeline overview: mRNA vaccines and therapeutics in development. Retrieved from https://www.modernatx.com/pipeline

Nascimento, I. P., & Leite, L. C. C. (2012). Recombinant vaccines and the development of new vaccine strategies. Brazilian Journal of Medical and Biological Research, 45(12), 1102-1111.

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.

Pfizer Inc. (2023). Pfizer pipeline: vaccines and therapeutics in development. Retrieved from https://www.pfizer.com/science/drug-product-pipeline

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine, 383(27), 2603-2615.

Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Therapeutic Delivery, 7(5), 319-334.

Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13(10), 759-780.

Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. (2021). mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. International Journal of Pharmaceutics, 601, 120586.

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019). Three decades of messenger RNA vaccine development. Nano Today, 28, 100766.

Weissman, D. (2015). mRNA transcript therapy. Expert Review of Vaccines, 14(2), 265-281.

World Health Organization. (2023). Global vaccine market report 2023. Geneva: World Health Organization Press.

Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019). Advances in mRNA vaccines for infectious diseases. Frontiers in Immunology, 10, 594.

---

[Internal Medicine -Home]

 

Video Section

Check out our extensive video library (see channel for our latest videos)

---

 

Recent Articles

• Micro-Behaviors and Macro-Mindsets: An Analysis of Subtle Human Reactions
• Burnout vs. Breakthrough: Why Some Doctors Find Joy Again After Leaving Clinical Practice
• The Truth About Physician Financial Myths: What Most Doctors Get Wrong
• Revisiting Lyme Disease Management in Primary Care
• The Psychology of Everyday Life: How Small Behaviors Reflect Deep Cognitive and Emotional Processes
• Managing ADHD in Adults: A Growing Primary Care Responsibility
• Raw Honey and Early Morning Awakening: Clinical Considerations
• Hemophilia Prophylaxis in the Era of Non-Factor Therapies
• Hidden Cognitive Decline Symptoms: What Every Internist Must Know Today
• Alternative Therapies for Depression: Breakthrough Neurostimulation Methods Show 80% Success Rate
• Pediatric Sepsis: Can Rapid Genomic Diagnostics Save Lives?
• Psychedelics for Acute Suicidality: Could the ED Become the Frontline?
• Pulse Pressure Variation: The Missing Key to Fluid Responsiveness in ED
• Screen Time, Social Media, and Teen Mental Health: What Can Family Physicians Do?
• Should Family Physicians Routinely Screen for Depression and Anxiety?
• Why Standard Blood Pressure Targets After Surgery May Be Harming Your Patients
• Evidence-Based Insights into Everyday Human Behavior
• Fascinating Psychological Insights- Evidence-Based Observations About How the Human Mind and Behavior
• Glycine’s Role in Sleep Enhancement- Clinical Evidence, Mechanisms, and Therapeutic Applications
• Early Morning Awakening Syndrome- Understanding Cortisol Dysregulation
• Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention
• Tachyphylaxis in Antidepressants: The Science Behind Treatment Resistance
• The Opioid Crisis in Family Practice: Safe Prescribing vs. Abandoning Patients
• 70 Psychology Facts That Explain How the Mind and Behavior Interact
• 100 Timeless Lessons for Growth, Success, and Happiness — With Healthcare Applications
• The Hidden Patterns of the Human Mind Evidence-Based Insights
• Asthma vs. COPD in Primary Care: Are We Missing Asthma-COPD Overlap?
• Lung Cancer Screening in Primary Care: Why Uptake Remains Low
• The Hidden Cost of Skipping Frailty Assessment: New Research Reveals
• The Spectrum of AI Influence- Comparative Impact Across Medical Specialties

   

---